Minimal residual disease monitoring in radically treated non-small cell lung cancer: challenges and future directions | O’Sullivan HM, et al | OncoTargets and Therapy | Dec. 2023

O’Sullivan HM, Feber A, Popat S. Minimal residual disease monitoring in radically treated non-small cell lung cancer: challenges and future directions. OncoTargets and Therapy. 2023;249-59.

Nonacus product: Oncology

Abstract

Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is still not defined. Whilst promising, the clinical utility of this technology to guide patient care is still investigational in non-small cell lung cancer (NSCLC) and has not entered routine care. Once technically and clinically optimized, MRD may be utilized to personalize adjuvant therapy, detect disease relapse earlier and improve cure rates. In this review, we discuss the current status of MRD monitoring in NSCLC by summarizing frequently used MRD assays and their associated evidence in NSCLC. We discuss the potential applications of these technologies and the challenge of demonstrating MRD clinical utility in trials.